Rodman & Renshaw Initiates Coverage on MediciNova (MNOV) with an Outperform
More News related to MNOV
- Notable Mergers and Acquisitions of the Day 6/25: DBRN/TWB, MNOV/AVGN, AA/NE
- MediciNova (MNOV) To Acquire Avigen (AVGN) For $4/Share
- MediciNova and Avigen Confirm Understanding for Key Terms for a Business Combination
- Arlene Morris Joins MediciNova's Audit Committee
- MediciNova Announces Plan to Modify Its Phase II Placebo-Controlled Clinical Trial Evaluating MN-221 in Patients With Severe, Acute Exacerbations of Asthma
Rodman & Renshaw initiates coverage on MediciNova (Nasdaq: MNOV) with an Outperform. Price target $9.
MediciNova, Inc. is a biopharmaceutical company focused on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the United States market.
Related Categories
New CoverageStocks Mentioned
+0.20Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
